• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BJU international >Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database.
【24h】

Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database.

机译：前列腺切除术后男性前列腺特异性抗原复发性前列腺癌患者的长期总体生存和无转移生存：国家前列腺疾病研究中心数据库的分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: * To describe metastasis-free survival (MFS) and overall survival (OS) among men with prostate-specific antigen (PSA)-recurrent prostate cancer after radical prostatectomy who did not receive additional therapy until metastasis, using a multicentre database capturing a wide ethnic mix. PATIENTS AND METHODS: * A retrospective analysis of the Center for Prostate Disease Research National Database (comprised of five US military hospitals and one civilian centre) was performed for patients with PSA relapse (>/= 0.2 ng/mL) after radical prostatectomy who had no additional therapy until the time of radiographic metastatic disease. * We investigated factors influencing metastasis and all-cause mortality using univariate and multivariate Cox regression analysis. RESULTS: * There were a total of 346 men who underwent radical prostatectomy between May 1983 and November 2008 and fulfilled the entry criteria. All patients had information on survival and 190 men had information on metastasis. Among patients with survival data (n= 346), 10-year OS was 79% after a median follow-up of 8.6 years from biochemical recurrence. * Among men with metastasis data (n= 190), 10-year MFS was 46% after a median follow-up of 7.5 years. * In Cox regressions, four clinical factors (Gleason score, pathological stage, time to PSA relapse and PSA doubling time), as well as age, were predictive of OS and/or MFS in univariate analysis, although only PSA doubling time (>/= 9 vs 3-8.9 vs <3 months) remained independently predictive of these outcomes in multivariate analysis (P < 0.001). CONCLUSIONS: * This multicentre multi-ethnic dataset shows that OS and MFS can be extensive for men with PSA-recurrent prostate cancer, even in the absence of further therapy before metastasis. * This unique patient cohort, the second largest of its type after the Johns Hopkins cohort, confirms that PSA doubling time is the strongest determinant of OS and MFS in men with PSA-recurrent disease. * Longer follow-up and more events will be required to determine whether other variables may also contribute to these outcomes.
机译：目的：*利用多中心数据库记录前列腺癌根治性前列腺切除术后复发前未接受其他治疗的男性前列腺特异性抗原（PSA）复发前列腺癌患者的无转移生存期（MFS）和总体生存期（OS）。种族混合。患者与方法：*对前列腺癌根治性前列腺切除术后复发的PSA复发患者（> / = 0.2 ng / mL）进行了前列腺疾病研究国家数据库（包括5家美国军事医院和1家民用中心）的回顾性分析。直到影像学上的转移性疾病发生时才进行其他治疗。 *我们使用单因素和多因素Cox回归分析调查了影响转移和全因死亡率的因素。结果：*在1983年5月至2008年11月之间，共有346例接受了前列腺癌根治术的男性患者符合入组标准。所有患者都有生存信息，190名男性有转移信息。在有生存数据的患者（n = 346）中，生化复发的中位随访时间为8.6年，10年OS为79％。 *在有转移数据的男性（n = 190）中，中位随访7.5年后，10年MFS为46％。 *在Cox回归中，单因素分析中的四个临床因素（格里森评分，病理分期，PSA复发时间和PSA加倍时间）以及年龄可预测OS和/或MFS，尽管只有PSA加倍时间（> / = 9 vs 3-8.9 vs <3个月）在多变量分析中仍然独立地预测了这些结果（P <0.001）。结论：*该多中心多族裔数据集显示，即使没有转移前的进一步治疗，OS和MFS对于PSA复发性前列腺癌的男性也可能广泛。 *这一独特的患者队列是继约翰·霍普金斯大学队列之后的第二大患者队列，证实了PSA加倍时间是PSA复发性疾病男性OS和MFS的最强决定因素。 *需要更长的随访时间和更多的事件来确定其他变量是否也可能有助于这些结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号